Streetbeat News

Analyst Ratings

ASND

Citigroup analyst David Lebowitz has maintained a Buy rating on Ascendis Pharma and increased the price target from $178 to $207.

Portfolio Pulse from Benzinga Newsdesk

September 17, 2024 | 3:21 pm

MU

Citigroup analyst Christopher Danely maintains a Buy rating on Micron Technology but lowers the price target from $175 to $150.

Portfolio Pulse from Benzinga Newsdesk

September 17, 2024 | 3:20 pm

BBIO

HC Wainwright & Co. has reiterated its Buy rating for BridgeBio Pharma (NASDAQ:BBIO) and maintained a price target of $43, indicating confidence in the company's future performance.

Portfolio Pulse from Benzinga Newsdesk

September 17, 2024 | 3:19 pm

VVI

Oppenheimer analyst Tyler Batory has reiterated an 'Outperform' rating for Viad Corp (NYSE:VVI) and maintained a price target of $41.

Portfolio Pulse from Benzinga Newsdesk

September 17, 2024 | 3:18 pm

GM

The options market shows a bearish sentiment towards General Motors (GM), with 45% of trades being bearish. The stock is currently priced at $47.88, up 2.15%, but analysts have mixed ratings with a consensus target of $43.0. Wells Fargo maintains an Underweight rating with a $33 target, while Deutsche Bank downgraded to Hold with a $53 target.

Portfolio Pulse from Benzinga Insights

September 17, 2024 | 3:16 pm

ASTS

Recent options activity for AST SpaceMobile (NASDAQ:ASTS) shows a mix of bullish and bearish sentiment among large investors, with significant trades in both calls and puts. Analysts maintain positive ratings with high price targets, indicating potential growth.

Portfolio Pulse from Benzinga Insights

September 17, 2024 | 3:16 pm

CAPR

HC Wainwright & Co. has reiterated its Buy rating for Capricor Therapeutics, maintaining a price target of $40. This suggests confidence in the company's future performance.

Portfolio Pulse from Benzinga Newsdesk

September 17, 2024 | 3:14 pm

RXO

Oppenheimer analyst Scott Schneeberger has reiterated an Outperform rating on RXO, maintaining a price target of $31.

Portfolio Pulse from Benzinga Newsdesk

September 17, 2024 | 3:14 pm

CGEM

HC Wainwright & Co. has reiterated its Buy rating on Cullinan Therapeutics (NASDAQ:CGEM) and maintained a price target of $28, indicating confidence in the company's future performance.

Portfolio Pulse from Benzinga Newsdesk

September 17, 2024 | 3:10 pm

JEF

Jefferies Financial shares rose after UBS initiated coverage with a Buy rating and set a $67 price target.

Portfolio Pulse from Benzinga Newsdesk

September 17, 2024 | 3:10 pm